Literature DB >> 22200940

Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma.

Eriko Goto1, Ryota Masuzaki, Ryosuke Tateishi, Yuji Kondo, Jun Imamura, Tadashi Goto, Hitoshi Ikeda, Masaaki Akahane, Shuichiro Shiina, Masao Omata, Haruhiko Yoshida, Kazuhiko Koike.   

Abstract

BACKGROUND: We evaluated the sensitivity and specificity of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography (CEUS) using perflubutane microbubbles (Sonazoid) in comparison with conventional B-mode ultrasonography (US) for the detection of hepatocellular carcinoma (HCC) nodules.
METHODS: A total of 100 treatment-naïve HCC patients admitted at our hospital between December 2007 and June 2009 were consecutively enrolled. The sensitivity and specificity of conventional and contrast-enhanced US were evaluated on a liver segment basis using dynamic CT as a reference standard. Movie files of conventional and enhanced US were stored separately for each segment (e.g., lateral, medial, anterior, and posterior) and reviewed randomly by two blinded readers.
RESULTS: A total of 138 HCC nodules (mean diameter 20.3 mm) were detected in 123 of 400 segments. Detection sensitivity of B-mode US was 0.837 for reader A and 0.846 for reader B, and that of CEUS was 0.732 for reader A and 0.831 for reader B. Specificity of B-mode US was 0.902 for reader A and 0.949 for reader B, and that of CEUS was 0.986 for reader A and 0.978 for reader B. CEUS false positives were mainly due to misidentification of hepatic cysts. A significant proportion of false-negative nodules are hyperechoic in B-mode US, likely because echogenicity hampers visualization of the defect in Kupffer imaging.
CONCLUSIONS: Kupffer imaging by CEUS with Sonazoid showed very high specificity but rather mediocre sensitivity for HCC detection. CEUS is highly suitable for confirmatory diagnosis of HCC; however, caution should be exercised in reaching a diagnosis based only on CEUS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200940     DOI: 10.1007/s00535-011-0512-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres.

Authors:  Grete Mørk Kindberg; Helge Tolleshaug; Norbert Roos; Tore Skotland
Journal:  Cell Tissue Res       Date:  2003-02-27       Impact factor: 5.249

3.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

4.  Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells.

Authors:  Kyosuke Yanagisawa; Fuminori Moriyasu; Takeo Miyahara; Miyata Yuki; Hiroko Iijima
Journal:  Ultrasound Med Biol       Date:  2007-02       Impact factor: 2.998

5.  Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.

Authors:  Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

6.  Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial.

Authors:  Fuminori Moriyasu; Kouichi Itoh
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

7.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

8.  Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.

Authors:  Thomas J Vogl; Wolfram Schwarz; Stefan Blume; Michael Pietsch; Kohkan Shamsi; Martina Franz; Hartmut Lobeck; Thomas Balzer; Kelly del Tredici; Peter Neuhaus; Roland Felix; Renate M Hammerstingl
Journal:  Eur Radiol       Date:  2002-09-10       Impact factor: 5.315

9.  Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver.

Authors:  M Tanaka; O Nakashima; Y Wada; M Kage; M Kojiro
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

10.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

View more
  9 in total

Review 1.  Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Mirella Fraquelli; Tin Nadarevic; Agostino Colli; Cristina Manzotti; Vanja Giljaca; Damir Miletic; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

Review 2.  Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.

Authors:  Hitoshi Maruyama; Tadashi Sekimoto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2015-12-22       Impact factor: 6.772

Review 3.  The role of intraoperative ultrasonography in the diagnosis and management of focal hepatic lesions.

Authors:  Ijin Joo
Journal:  Ultrasonography       Date:  2015-04-06

Review 4.  Contrast-enhanced ultrasonography: advance and current status in abdominal imaging.

Authors:  Yong Eun Chung; Ki Whang Kim
Journal:  Ultrasonography       Date:  2014-09-12

5.  Added Value of Contrast-Enhanced Ultrasound on Biopsies of Focal Hepatic Lesions Invisible on Fusion Imaging Guidance.

Authors:  Tae Wook Kang; Min Woo Lee; Kyoung Doo Song; Mimi Kim; Seung Soo Kim; Seong Hyun Kim; Sang Yun Ha
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

6.  Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.

Authors:  Ji Hoon Park; Mi-Suk Park; So Jung Lee; Woo Kyoung Jeong; Jae Young Lee; Min Jung Park; Kyunghwa Han; Chung Mo Nam; Seong Ho Park; Kyoung Ho Lee
Journal:  BMC Cancer       Date:  2017-04-18       Impact factor: 4.430

7.  Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016.

Authors:  Juanjuan Zhang; Yanyan Yu; Ying Li; Lunshou Wei
Journal:  Oncotarget       Date:  2017-08-07

Review 8.  Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.

Authors:  Junghoan Park; Jeong Min Lee; Tae-Hyung Kim; Jeong Hee Yoon
Journal:  Clin Mol Hepatol       Date:  2021-12-27

Review 9.  Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines.

Authors:  Liliana Chiorean; Claudio Tana; Barbara Braden; Cosmin Caraiani; Zeno Sparchez; Xin-Wu Cui; Ulrich Baum; Christoph F Dietrich
Journal:  Med Princ Pract       Date:  2016-06-17       Impact factor: 1.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.